Daiwa Securities Group
SABS icon

Daiwa Securities Group’s SAB Biotherapeutics SABS Stock Holding History

Daiwa Securities Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13
Closed – – 1377
2022
Q3 		$0 Hold
13
– – ﹤0.01% 1387
2022
Q2 		$0 Hold
13
– – ﹤0.01% 1418
2022
Q1 		$0 Hold
13
– – ﹤0.01% 1410
2021
Q4 		$1K Buy
+13
New +$1.22K ﹤0.01% 1359

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Daiwa Securities Group's SABS Position: Q4 2022 in Review

Daiwa Securities Group sold out of SAB Biotherapeutics (SABS) in Q4 2022, closing a stake of 13 shares.

Daiwa Securities Group first reported a position in SABS in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q4 2021. 38 funds tracked by Wall St. Rank hold SABS as of Q4 2022.

  • Daiwa Securities Group reported no remaining SAB Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Daiwa Securities Group sold 13 SAB Biotherapeutics shares in Q4 2022.
  • Daiwa Securities Group first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 4 quarters.
  • Daiwa Securities Group's SAB Biotherapeutics position peaked at $1K in Q4 2021.
  • 38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2022.

Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.